Human medicines European public assessment report (EPAR): Zessly, infliximab, Arthritis, Psoriatic;Psoriasis;Crohn Disease;Arthritis, Rheumatoid;Colitis, Ulcerative;Spondylitis, Ankylosing, Date of authorisation: 18/05/2018, Revision: 12, Status: Authori

Human medicines European public assessment report (EPAR): Zessly, infliximab, Arthritis, Psoriatic;Psoriasis;Crohn Disease;Arthritis, Rheumatoid;Colitis, Ulcerative;Spondylitis, Ankylosing, Date of authorisation: 18/05/2018, Revision: 12, Status: Authorised

Lomustine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001902/202301

Lomustine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001902/202301

Human medicines European public assessment report (EPAR): Cyramza, ramucirumab, Stomach Neoplasms, Date of authorisation: 19/12/2014, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Cyramza, ramucirumab, Stomach Neoplasms, Date of authorisation: 19/12/2014, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Pravafenix, fenofibrate,pravastatin, Dyslipidemias, Date of authorisation: 14/04/2011, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Pravafenix, fenofibrate,pravastatin, Dyslipidemias, Date of authorisation: 14/04/2011, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Tecartus, Brexucabtagene autoleucel, Lymphoma, Mantle-Cell, Date of authorisation: 14/12/2020, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Tecartus, Brexucabtagene autoleucel, Lymphoma, Mantle-Cell, Date of authorisation: 14/12/2020, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Orserdu, elacestrant, Breast Neoplasms, Date of authorisation: 15/09/2023, Status: Authorised

Human medicines European public assessment report (EPAR): Orserdu, elacestrant, Breast Neoplasms, Date of authorisation: 15/09/2023, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness